InVitria

07/08/2026

*Poster Alert*
How much does a single defined component shape hiPSC proliferation and cardiac differentiation? It's a question we set out to answer with . Paul Burridge's lab at Northwestern Medicine.

At ISSCR 2026 in Montreal, Stathos and Paul Burridge are presenting joint work exploring how chemically defined recombinant human albumin supports hiPSC growth and more consistent cardiac differentiation, including in weekend-free, protein-free conditions.

🧬 Poster
🗓️ Presentation: Friday, July 10 at 5:15 PM EST
📍 ISSCR 2026 | Palais des congrès de Montréal

's Mark Stathos and Elliott Renft will be on-site to walk through the data. If you're at ISSCR, stop by F1392 or reach out — we'd love to talk.

We're proud of what came out of this work with the Burridge Lab, and there's more to the story than a single poster can hold.

07/06/2026

Batch-to-batch variability shouldn't be the thing standing between your stem cell process and the clinic.

The team is attending in Montreal, and we're bringing the science behind animal-free, recombinant proteins built for reproducible stem cell culture — across expansion, differentiation, formulation, and cryopreservation.

🗓️ July 8–11, 2026 | Palais des congrès de Montréal

Elliott Renft and Mark Stathos from our Product Applications team will be on-site to walk through how ITSE Animal-Free, Cellastim S (recombinant human albumin), and Optiferrin (recombinant transferrin) support defined, xeno-free workflows from scale-up through cryopreservation — batch after batch.

We'll also be sharing a poster presentation at the meeting — details announced soon. Stay tuned.

Working on a serum-free transition? Let's talk. Comment or DM to set up time with our team.

06/04/2026

Lentiviral vectors can lose infectious titer during downstream processing steps like TFF, sterile filtration, freeze-thaw, and process holds.
InVitria’s latest poster shows how Optibumin® 25 recombinant human serum albumin supported LVV stability and recovery across multiple DSP stress conditions.
The data was presented at ASGCT 2026 in Boston.
Download the poster: https://hubs.ly/Q04k7wN60

InVitria is a global leader in blood-free, chemically defined media & supplements that support the approval of life-changing medicines.

05/13/2026

Join InVitria at ASGCT 2026 in Boston to see new data on reduced-DMSO cryopreservation using recombinant albumin.

Mark Stathos, PhD, Applications Scientist at InVitria, will present Poster #2182:
“Enhanced Cryopreservation of Therapeutically Relevant Cells: Superior Performance of Recombinant Albumin and Its Role in Reducing DMSO Dependency.”

The poster highlights post-thaw performance data across T cells, MSCs, and iPSCs, including viability, expansion, apoptosis, and pluripotency outcomes under reduced-DMSO conditions.

Stop by Poster #2182 to discuss the data with our team.

05/12/2026

Join InVitria at ASGCT 2026 today as Mark Stathos, PhD presents new data on recombinant animal-free albumin for lentiviral vector manufacturing and downstream processing.

The presentation will highlight how recombinant albumin helped:
• Improve infectious lentiviral vector yields
• Preserve vector titers during sterile filtration
• Support downstream processing and final formulation workflows

📍 Room 162AB
🕓 Today at 4:45 PM
📍 Visit InVitria at Booth #909

Don't forget our POSTER # 2182 on Cryopreservation of Therapeutic Cells using LOWER DMSO!!!!!

05/11/2026

Heading to ASGCT 2026? Stop by Booth #909 to meet the InVitria team and learn how recombinant, animal-origin-free proteins are supporting gene and cell therapy workflows.

We’ll also be presenting about how to enhancing infectious lentiviral vector yields.
Title: Recombinant Animal-Free Albumin Enhances Infectious Lentiviral Vector Yields By Stabilizing Viral Particles During Downstream Processing and Final Formulation.
Presented by Mark Stathos, PhD
📍May 12 at 4:45 PM | Room 162AB

And presenting a poster:
📍 #2182
Title: Enhanced Cryopreservation of Therapeutically Relevant Cells: Superior Performance of Recombinant Albumin and Its Role in Reducing DMSO Dependency

See how recombinant albumin can support:
• Reduced-DMSO cryopreservation
• Post-thaw recovery
• Cell viability and expansion
• More defined manufacturing workflows

05/05/2026

Day 2 in Nashville and the booth has been the best seat in the house. 👋

After Scott's talk yesterday on the recombinant albumin journey, the questions kept coming — about Exbumin® for lyophilized formulations, Optibumin® 25 for closed-system GMP workflows, and what it really takes to move away from plasma-derived HSA.

These are our favorite kinds of conversations: real problems, real formulations, real timelines.

If you're at IPEC Excipient World, come find Scott, Elliott and Jake at Booth #328 — we're here through tomorrow. ☕️

05/04/2026

What does it take for a novel excipient to become a standard?

At the Biologics Summit, Scott Deeter broke down the recombinant albumin journey, including:
• Stability and performance considerations
• Regulatory path and adoption barriers
• Real-world use in approved biologics

Relevant for teams working on formulation, process consistency, or risk reduction.
The talk will be posted soon. Visit https://hubs.ly/Q04fjN6H0 to receive it directly

04/29/2026

InVitria is heading to ISCT Annual Meeting.

We’ll be onsite connecting with teams working on cell therapy development and manufacturing.

If you’re attending, plan to meet with
Marcus Curl, VP of Product Applications, and
Jake Hanks, Director of Business Development.

They’ll be discussing how animal-origin-free, chemically defined proteins support:

Consistent cell expansion
Scalable manufacturing
Reduced variability across workflows

If you’re working on process development or scale-up, reach out ahead of the meeting to connect.

04/28/2026

Recombinant albumin is already used in approved biologics.

At IPEC Excipient World 2026, we’re sharing how Exbumin® and Optibumin® 25 support:
• formulation stability
• lot-to-lot consistency
• scalable GMP manufacturing

See the full announcement: https://hubs.ly/Q04dQB6L0

InVitria is a global leader in blood-free, chemically defined media & supplements that support the approval of life-changing medicines.